Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
August 28, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for April 30, 2007 Subscribe to this News Feed      
 

Acquisition of Sunrise Technologies' Assets Completed by PriaVision, Inc., Including Hyperion LTK System Technology, the Entire Instrument Inventory, Patents, Other Intellectual Property

After years of remarkably expensive litigation, PriaVision, Inc. has acquired all of the assets of Sunrise Technologies International, Inc., including its Hyperion LTK System. PriaVision founders David A. Brewer (president) and Satish Herekar (vice president and chief scientist) now ready to expand their opthalmic instruments business. The company develops innovative technology for presbyopia, cross-linking, augmentation, and capsular lens-filling. Products under development include KeraCure™, PriaWave™ and PriaGel™.

San Francisco, CA (PRWEB) April 30, 2007 -- Following a court-ordered sale, all the remaining assets of Sunrise Technologies International, Inc. have been acquired by PriaVision, Inc. With the addition of these intellectual property assets, all the assets of Sunrise and its Hyperion® LTK System are now owned by PriaVision, which plans to expand the Hyperion business and to support Sunrise's former customers.

The patented, no-touch technology used in the Hyperion LTK System allows an ophthalmic surgeon to correct mild to moderate farsightedness in an FDA approved procedure that requires only moments in an outpatient setting. PriaVision plans to upgrade existing instruments with new technology that is currently being developed and tested.

PriaVision's battle to acquire ownership and control of Sunrise's business dates back to 2002, the year when Sunrise became insolvent and filed Chapter 7 bankruptcy. Disputes with a large creditor that initiated several legal actions required years of expensive litigation to resolve. A company owned by David A. Brewer, 21X Capital Ltd., funded these legal battles and eventually prevailed in the unusually tenacious battle between Sunrise creditors. (This case was decided 10/12/05 in Superior Court of California, County of Santa Clara, case no. 1-03-CV 816191, but had been appealed until this week.)

During this time, however, Satish Herekar led a very productive development effort to refine and extend the Hyperion's capabilities. In addition, Mr. Herekar, who had been Sunrise's chief design manager for the Hyperion, developed breakthrough technologies for new ophthalmic products. Versions of those products will be tested in clinical trials and brought to market in future years.

"PriaVision's KeraCure™, PriaWave™, and PriaGel™ products will enable ophthalmic physicians to bring outstanding benefits to their patients", said Mr. Herekar. "Our design mandate is to provide unique solutions that are minimally invasive and minimize side effects. I am very proud of the innovations our development team has underway in cross-linking, augmentation, and capsular lens-filling."

"Now that we have the litigation finally out of the way", said Mr. Brewer, "we intend to move forward and grow this business. Our first priority, though, is to strengthen the support of Hyperion customers here in the U.S. and internationally. We believe in this improved technology and plan to make it successful for our customers and their patients."

PriaVision was founded in 2002 and is located in Menlo Park, California. David A. Brewer is its President and Satish Herekar its Vice President and Chief Scientist.
                                                                        
For more information, contact David Brewer 1-650-566-8000.

END
###

See the original story at: http://www.prweb.com/releases/2007/04/prweb522600.htm
OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
David Brewer
PriaVision
1-650-566-8000
Email us Here
ATTACHED FILES

PriaVision's Hyperion LTK System
The Hyperion LTK System is an FDA-approved device used by ophthalmic surgeons for the temporary reduction of hyperopia in patients with +0.75 to +2.5 diopters of manifest refraction spherical equivalent (MRSE) at the spectacle plane (with cylinder less than or equal to + or - 0.75 diopters) who are 40 years of age or older with documented stability of refraction for the prior 6 months, as demonstrated by a change of less than or equal to 0.50D in spherical and cylindrical components of manifest refraction. The magnitude of correction with this treatment diminishes over time, with some patients retaining some or all of their refractive correction. Based on existing information for the clinical parameters used in the clinical trial, Sunrise Technologies' model for the average longevity for the procedure indicates that some of the effect lasts 10 years or beyond. Age related drift towards hyperopia contributes to the loss of effect after the initial two years.

The Hyperion LTK System
Over 190 Hyperion LTK systems have been sold and installed throughout the U.S.A.

Patient ready for Hyperion LTK treatment
The procedure takes only seconds, with very little recovery time.

Hyperion LTK System
The Hyperion LTK System is an FDA-approved device used by ophthalmic surgeons for the temporary reduction of hyperopia in patients with +0.75 to +2.5 diopters of manifest refraction spherical equivalent (MRSE) at the spectacle plane (with cylinder less than or equal to + or - 0.75 diopters) who are 40 years of age or older with documented stability of refraction for the prior 6 months, as demonstrated by a change of less than or equal to 0.50D in spherical and cylindrical components of manifest refraction. The magnitude of correction with this treatment diminishes over time, with some patients retaining some or all of their refractive correction. Based on existing information for the clinical parameters used in the clinical trial, Sunrise Technologies' model for the average longevity for the procedure indicates that some of the effect lasts 10 years or beyond. Age related drift towards hyperopia contributes to the loss of effect after the initial two years.

David A. Brewer, PriaVision co-founder

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright